Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott sues DexCom over glucose monitoring system
DexCom has said that it believes the complaint to be without merit, and it intends to “vigorously contest the action”. In a statement DexCom remarked. “DexCom…believes the complaint
DexCom has said that it believes the complaint to be without merit, and it intends to “vigorously contest the action”. In a statement DexCom remarked. “DexCom…believes the complaint
The trial will compare the effects of the combination of nimotuzumab with radiation, against radiation alone in patients with stage IIB and III forms of the disease. The
Under the terns of the agreement, Dimethaid Research has received an up-front payment, a share in operating profits above minimum targets and a long-term supply agreement. “Pennsaid offers
The study, with targeted enrollment of 211 patients at approximately 40 trial centers in the US and Europe, is designed to establish the safety and effectiveness of Troxatyl
Genmab has completed treatment of 33 patients in a phase I/II dose escalation trial and expanded the study into a phase II trial, which will include 200 additional
The tablets are an AB-rated generic equivalent of GlaxoSmithKline’s antidepressant Paxil. New drug applications for generic drugs are termed “abbreviated” because they are generally not required to include
Sweden’s Semper AB has licensed the acids, known as DHA and ARA, for use in infant formulas in territories including Finland, Sweden, Latvia and Lithuania, whilst Korea’s Pasteur
Researchers at Natural Selection will adapt neural network architectures for the reliable and accurate prediction of functional RNA (fRNA) genes including microRNAs. The effort, funded under a phase
The company is the country’s sole provider of the formula, which was created to help reduce the risk against AIDS transmission between mother and baby. In South Africa
In a final attempt to get its products returned to the market quickly enough to save the business, Able had asked the FDA to wave its usual review